Functional Dyspepsia: Advances in Diagnosis and Therapy.
- Author:
Nicholas J TALLEY
1
Author Information
- Publication Type:Review
- Keywords: Functional dyspepsia; Epidemiology
- MeSH: Anxiety; Cytokines; Diagnosis*; Dyspepsia*; Eosinophilia; Epidemiology; Gastroenteritis; Gastroesophageal Reflux; Heartburn; Humans; Inflammation; Natural History; Necrosis; Risk Factors; T-Lymphocytes
- From:Gut and Liver 2017;11(3):349-357
- CountryRepublic of Korea
- Language:English
- Abstract: Functional dyspepsia (FD) is a common but under-recognized syndrome comprising bothersome recurrent postprandial fullness, early satiety, or epigastric pain/burning. Epidemiologically, there are two clinically distinct FD syndromes (although these often overlap clinically): postprandial distress syndrome (PDS; comprising early satiety or meal-related fullness) and epigastric pain syndrome. Symptoms of gastroesophageal reflux disease overlap with FD more than expected by chance; a subset has pathological acid reflux. The pre-test probability of FD in a patient who presents with classical FD symptoms and no alarm features is high, approximately 0.7. Coexistent heartburn should not lead to the exclusion of FD as a diagnosis. One of the most exciting observations in FD has been the consistent finding of increased duodenal eosinophilia, notably in PDS. Small bowel homing T cells, signaling intestinal inflammation, and increased cytokines have been detected in the circulation, and elevated tumor necrosis factor-α levels have been significantly correlated with increased anxiety. Postinfectious gastroenteritis is a risk factor for FD. Therapeutic options remain limited and provide only symptomatic benefit in most cases. Only one therapy is known to change the natural history of FD–Helicobacter pylori eradication. Treatment of duodenal eosinophilia is under investigation.
